Study Stopped
Terminated following the completion of ImpACT-24B study
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
A Sub-Study of the ImpACT-24B Trial (CLP1000500) Assessing Brain Collateral Blood Flow Enhancement Following Spheno-Palatine Ganglion (SPG) Stimulation in Subjects With Acute Ischemic Stroke
1 other identifier
observational
1
1 country
1
Brief Summary
The purpose of the ImpACT-24col sub-study is to explore effect of SPG stimulation on the augmentation of collateral blood flow and to relate it to the subject's cerebral blood flow status, the extent of the collateral vessel potency prior to the stimulation and the relation of the vessel occlusion site to the vasodilatory effect by using digital subtraction angiography (DSA), the gold standard imaging technique to demonstrate collateral blood flow dynamics. The results of this study will further promote the knowledge towards optimization of SPG stimulation to treat acute ischemic stroke patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 25, 2017
CompletedFirst Submitted
Initial submission to the registry
September 27, 2017
CompletedFirst Posted
Study publicly available on registry
January 11, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 3, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 3, 2018
CompletedApril 24, 2019
April 1, 2019
8 months
September 27, 2017
April 23, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Collateral blood flow grades difference following SPG stimulation.
The difference between the collateral blood flow grades, assessed by DSA, at baseline and following SPG stimulation.
Day 1
Study Arms (1)
Acute Isch. Stk pts treat. w/SPG stimul.
Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol. Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed. Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle. The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol.
Eligibility Criteria
Subjects with Acute Ischemic Stroke in the anterior circulation enrolled to the ImpACT-24B study.
You may not qualify if:
- Additionally, subjects will be excluded from the ImpACT-24col sub-study if DSA is contraindicated (such as allergy to the contract media, etc.).
- Age: Between 40 years and 80 years for male and 85 for female subjects
- Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior Cerebral Artery territories
- Imaging findings demonstrating signs of ischemia in the anterior circulation, consistent with the clinical diagnosis
- Baseline NIHSS ≥ 7 and ≤ 18 within 2 hours prior to implantation.
- Ability to initiate treatment within 8- 24 hours from stroke onset
- Signed informed consent from patient him/herself or legally authorized representative if applicable
- Intracranial hemorrhage or hemorrhagic transformation
- Massive stroke
- Acute ischemic stroke in the posterior circulation
- Minor stroke
- Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke
- Previous stroke in the last 6 months or pre-existing disability
- Patients with bleeding propensity or any condition in the oral cavity that prevents implantation
- Clinical signs and symptoms or imaging evidence of bilateral stroke.
- +8 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- BrainsGatelead
Study Sites (1)
High Technology Medical Center University Clinic LTD.
Tbilisi, 0144, Georgia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Yoram Slolberg, Dr.
BrainsGate
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 27, 2017
First Posted
January 11, 2018
Study Start
September 25, 2017
Primary Completion
June 3, 2018
Study Completion
June 3, 2018
Last Updated
April 24, 2019
Record last verified: 2019-04